Roche deal closes, Phase 3 starts, Sanofi milestone boosts Nurix
Roche collaboration closes with $700M upfront Nurix closed its global collaboration with Roche for bexobrutideg after antitrust clearance, receiving $700 million upfront and eligibility for up to $2.3 billion in milestones. This huge cash infusion strengthens Nurix's balance sheet and validates its BTK degrader, pushing the stock up.
The closing of the Roche deal is a major new event that directly boosts Nurix's capital and credibility.
First patient enrolled in Phase 3 DAYBreak CLL-306 trial Nurix enrolled the first patient in a pivotal Phase 3 trial of bexobrutideg for relapsed/refractory CLL/SLL, comparing it to standard-of-care pirtobrutinib. This advances the drug toward potential approval, increasing the chance of future revenue and lifting investor confidence.
The Phase 3 start is a new clinical milestone that de-risks bexobrutideg and supports the stock's upside.
Sanofi milestone payment of $10 million Nurix received a $10 million milestone from Sanofi for starting a Phase 1 trial of an oral STAT6 degrader, bringing total Sanofi receipts to about $139 million. This non-dilutive cash and partner validation support the pipeline and strengthen the financial position.
The Sanofi milestone is a new cash event that reinforces Nurix's partnership strategy and financial health.
Biotech sector rally lifts Nurix to 52-week high Nurix shares climbed to $25.49 as part of a broad biotech rally on August 7, 2026, driven by sector-wide earnings and pipeline progress. While this reflects general market enthusiasm, it also highlights Nurix's recent positive news flow.
The sector rally is a new market event that contributed to Nurix's stock price increase, though it is less company-specific.